drugset / Trial / NCT03123978
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
Phase 1
Completed
6 enrolled
University of California, Davis
National Cancer Institute (NCI) · collabPandomedx · collab
NaSingle-groupOpen-labelTreatment
Summary
This phase I trial studies the best dose and side effects of niclosamide when given together with enzalutamide in treating patients with castration-resistant prostate cancer that has come back or has spread to other places in the body. Androgens can cause the growth of prostate cancer cells. Hormone therapy using enzalutamide may fight prostate cancer by lowering the amount of androgen the body makes and/or blocking the use of androgen by the tumor cells. Niclosamide may block signals that enhance prostate cancer cell growth. Giving enzalutamide and niclosamide may work better in treating patients with castration-resistant prostate cancer.
Timeline
- Start
- 2017-01-09
- Primary completion
- 2022-01-14
- Completion
- 2022-04-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | — | Oral |
| Subject | Niclosamide | Unknown | — | Oral |